These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 31917616)

  • 1. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
    Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
    Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
    Nagano T; Tachihara M; Nishimura Y
    Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
    Russo A; Lopes AR; McCusker MG; Garrigues SG; Ricciardi GR; Arensmeyer KE; Scilla KA; Mehra R; Rolfo C
    Curr Oncol Rep; 2020 Apr; 22(5):48. PubMed ID: 32296961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
    Halliday PR; Blakely CM; Bivona TG
    Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
    Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for NSCLC with driver mutations.
    Minuti G; D'Incecco A; Cappuzzo F
    Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 13. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
    Asao T; Takahashi F; Takahashi K
    Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
    Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
    Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
    Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapies for Lung Cancer.
    Stinchcombe TE
    Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of oncogene-driven non-small cell lung cancer.
    Kastelijn EA; de Langen AJ; Peters BJM
    Curr Opin Pulm Med; 2019 May; 25(3):300-307. PubMed ID: 30865033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging protein kinase inhibitors for non-small cell lung cancer.
    Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.